For more detailed technical specifications, you can access the full Guideline on Non-Clinical Studies for GTMPs via the official .
The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .
: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA. 125459
: This guideline is a cornerstone for developers of Advanced Therapy Medicinal Products (ATMPs) in the European Union.
: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements : For more detailed technical specifications, you can access
Guideline on the Non-Clinical Studies Required before First ... - EMA
This document outlines the essential safety and efficacy data that developers must generate during the "non-clinical" (animal or lab) phase to justify moving into human subjects. : This guideline is a cornerstone for developers
: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells.